Incretin-based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes-Reference-Cited by-同舟云学术

Incretin-based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

Published:2009-11 Issue: Volume:21 Page:623-630
ISSN:1041-2972
Container-title:Journal of the American Academy of Nurse Practitioners
language:en
Short-container-title:

Author:

Wick Allison,Newlin Kelley

Publisher

Wiley

Subject

General Nursing

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1745-7599.2009.00455.x/fullpdf

Reference49 articles.

1. GLP-1: Physiological effects and potential therapeutic applications;Aaboe;Diabetes Obesity and Metabolism,2008

2. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men;Agersø;Diabetologia,2002

3. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis;Amori;Journal of the American Medical Association,2007

4. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase;Bjornsdottir;Diabetologia,2008

5. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury;Bose;Diabetes,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison;Diabetes Research and Clinical Practice;2024-06

2. Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals;Life Sciences;2020-11

3. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance;Clinical Diabetes;2020-10-01

4. Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites;RSC Advances;2020

5. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis;BIOMED ENVIRON SCI;2020